GST department orders Rs 170 crore recovery from Aurobindo Pharma
AUROPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.9 pts more than Nifty Midcap 150 and 1.5 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
The GST department has passed 4 orders demanding recovery of refunds worth about Rs 169.84 crore (Rs 84.92 crore tax plus Rs 84.92 crore penalty) from Aurobindo's EOU Unit 3. The refunds relate to accumulated Input Tax Credit during September to December 2022 on zero-rated exports. The department claims similar products exist in the domestic market. The company says there is no material financial or operational impact and will appeal before the Commissioner of Central Tax (Appeals), Hyderabad. Writ petitions challenging Rule 89(4)(C) of CGST Rules are pending in the Telangana High Court.
Tax demand of about Rs 170 crore but company says no material financial impact and plans to appeal. Watch writ petition outcome.